Baidu
map

Circulation:替格瑞洛加入阿司匹林疗法不能改善冠脉搭桥术后的SVG阻塞率

2020-11-10 MedSci原创 MedSci原创

虽然使用了阿司匹林,但仍有15%的患者在冠状动脉搭桥手术(CABG)后的第一年内发生大隐静脉移植物(SVG)闭塞。POPular CABG试验探究在在CABG术后1年内,标准阿司匹林加上ticagre

虽然使用了阿司匹林,但仍有15%的患者在冠状动脉搭桥手术(CABG)后的第一年内发生大隐静脉移植物(SVG)闭塞。POPular CABG试验探究在在CABG术后1年内,标准阿司匹林加上ticagrelor(替格瑞洛)治疗是否可改善SVG的通畅情况。

该研究是一项多中心的、安慰剂为对照的随机双盲试验,将有≥1条SVG的冠状动脉搭桥术后患者随机分至替格瑞洛组或安慰剂组,两组患者均同时附有80或100mg的阿司匹林。主要评估指标是1年内的SVG阻塞率,次要指标为1年内SVG失败,包括SVG阻塞、SVG血运重建、SVG所在心肌区域引起的心肌梗塞或猝死。

主要预后的亚组分析

共499位受试者,平均67.9±8.3岁,87.1%的男性,31.3%的患者进行CABG的指征为急性冠状动脉综合征,其中95.2%的采用了体外循环。替格瑞洛组和安慰剂组分别有220位和223位患者可进行主要指标评估,两组的SVG阻塞率分别为10.5%和9.1%,优势比 1.29。替格瑞洛组和安慰剂组分别还发生了35例(14.2%)和29例(11.6%)SVG失败,优势比 1.22。

总之,在该随机对照研究中,在标准阿司匹林疗法中加入替格瑞洛并不能降低CABG术后1年内的SVG阻塞率。

原始出处:

Laura M. Willemsen, et al. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG). Circulation. 2020;142:1799–1807

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
    2021-06-05 tomyang96
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
    2020-12-23 1250ae30m32暂无昵称

    了解最新资讯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
    2020-11-12 zzc2214
  6. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
    2020-11-10 ms4000000062793346

    学习学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1663972, encodeId=5a9e16639e272, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Thu May 06 19:23:54 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696957, encodeId=26d1169695ef3, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Jun 05 12:23:54 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682087, encodeId=d671168208e98, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Sat Jul 10 05:23:54 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910433, encodeId=e0d791043351, content=了解最新资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201223/c6eb97e303a0474c8bd341fe1a942085/545949c563dd4214953a55c5311be8ff.jpg, createdBy=4e3b2534430, createdName=1250ae30m32暂无昵称, createdTime=Wed Dec 23 20:20:37 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492388, encodeId=5d49149238854, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552930, encodeId=d3e015529309c, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Nov 12 07:23:54 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898356, encodeId=e3db89835628, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43be5402548, createdName=ms4000000062793346, createdTime=Tue Nov 10 22:11:59 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898294, encodeId=eae289829496, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaKDyV12HfWgcibjBytYbUZPvahiblv9SVwsM6ZzZekMZ3EAMUWtFLlEO85IdxsSXiaUgEicLfsj1gdw/132, createdBy=989b2329301, createdName=沐子521, createdTime=Tue Nov 10 17:49:53 CST 2020, time=2020-11-10, status=1, ipAttribution=)]
    2020-11-10 沐子521

    感谢分享

    0

相关资讯

无合并症高血压患者中阿司匹林的合理应用

阿司匹林在降低心血管事件风险的同时可增加出血风险,近年来,阿司匹林在动脉粥样硬化性心血管疾病(ASCVD)一级预防中的地位一直备受争议。

Clin Gastroenterology H: 慢性丙型肝炎病毒感染患者每日接受阿司匹林治疗与肝细胞癌发生风险的关系

我们知道,阿司匹林疗法与降低结肠癌的风险有关,但是对于阿司匹林是否对丙型肝炎病毒(HCV)相关的肝细胞癌(HCC)的风险有影响目前还不清楚

Anesth Analg :研究表明,阿司匹林可以降低COVID-19住院患者的死亡风险

阿司匹林(Aspirin)自发明以来已有100多年历史,如今的它作为一种解热镇痛药已然走进千家万户。越来越多的研究表明阿司匹林对神经退行性疾病、癌症等重大疾病也有着一定的预防和治疗效用。

Neurology:阿司匹林对卒中和小动脉瘤破裂患者的安全性分析

阿司匹林对于伴有小UIA和ICD的患者是一种安全的治疗方法。高危组中未服用阿司匹林的患者应进行加强监护。

TCT 2020丨TICO-STEMI研究:在STEMI患者中应用替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗的随机临床试验

STEMI患者PCI后,多数采用不少于12个月的双联抗血小板治疗。高强度的抗血小板治疗虽然降低了缺血事件的发生,但同时也增加了出血风险。

阿司匹林将新冠COVID-19感染患者的死亡风险降低47%

与未服用阿司匹林的住院患者相比,服用阿司匹林的患者进重症监护病房(ICU)或连接机械呼吸机的比例大大降低。

Baidu
map
Baidu
map
Baidu
map